Avery Therapeutics
Pre-clinicalAvery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat diseases and injuries to human muscle. Avery’s lead product, MyCardia™, is being developed to address and treat heart failure.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $21.4M
About
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat diseases and injuries to human muscle. Avery’s lead product, MyCardia™, is being developed to address and treat heart failure.
Tissue Engineering
Funding History
7Total raised:$21.4M
Series A$5.5MSep 15, 2022
Grant$500KJun 15, 2021
Seed$2.1MJun 15, 2021
Series A$10MJun 15, 2020